{"id":44293,"date":"2025-10-24T22:55:54","date_gmt":"2025-10-24T14:55:54","guid":{"rendered":"https:\/\/flcube.com\/?p=44293"},"modified":"2025-10-24T22:55:54","modified_gmt":"2025-10-24T14:55:54","slug":"huadongs-mefatinib-approved-by-nmpa-for-egfr%e2%80%91driven-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=44293","title":{"rendered":"Huadong\u2019s Mefatinib Approved by NMPA for EGFR\u2011Driven NSCLC"},"content":{"rendered":"\n

Huadong Medicine (SHE: 000963<\/a>) announced that its Class\u202f1 innovative drug Mefatinib Tablets<\/strong> has received marketing approval from the National Medical Products Administration (NMPA). The approval designates Mefatinib as the first\u2011line therapy for adult patients with locally advanced or metastatic non\u2011small\u2011cell lung cancer (NSCLC) carrying the EGFR exon\u202f21 (L858R) substitution mutation.<\/p>\n\n\n\n

Key Product Highlights<\/strong><\/h3>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Drug<\/strong><\/td>Mefatinib Tablets (oral, irreversible EGFR\/HER2 inhibitor)<\/td><\/tr>
Indication<\/strong><\/td>First\u2011line therapy for EGFR L858R\u2011positive NSCLC<\/td><\/tr>
Regulatory Status<\/strong><\/td>NMPA Class\u202f1 innovative drug approval<\/td><\/tr>
Mechanism<\/strong><\/td>Covalent, irreversible inhibition of EGFR\/HER2 kinase domains \u2192 \u2193 ErbB signaling \u2192 tumor growth arrest<\/td><\/tr>
Intellectual Property<\/strong><\/td>Fully independent IP portfolio owned by Huadong Medicine<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical & Commercial Impact<\/strong><\/h3>\n\n\n\n